NeoPharm NEOL
-
Dropping Coverage of NeoPharm
We're dropping coverage of NeoPharm NEOL to focus our resources on other companies.
-
NeoPharm Reports 2007 Results
NeoPharm NEOL released 2007 financial results that were ..... clinical trials remains a strong focus at NeoPharm , we're still skeptical of the value ..... maintaining our fair value estimate. NeoPharm expects two of its liposomal chemotherapy …
-
NeoPharm under Review
We're putting NeoPharm NEOL under review as we investigate the stock's recent high volume and steep price increases. While management has not announced …
-
NeoPharm Still Has Hopes for IL13
NeoPharm NEOL announced 2006 financial results Tuesday ..... officer is set to end next week, and NeoPharm is currently searching for a replacement ..... With IL13 no longer in development, NeoPharm completed its organizational realignment …
-
Stock Star Rating Performance Review
… None Speculative 03-21-05 12-29-06* -87% Neopharm NEOL None Speculative 11-02-05 12-15-06 -78% Westwood ..... better, and any bad outcome much worse. Next comes Neopharm NEOL , a tiny biotech that cratered after a key drug failed …
-
MGI Dodges Gliadel Bullet
… small bullet Monday when competitor NeoPharm 's NEOL drug candidate for brain tumors ..... MGI as a result. We had assumed NeoPharm would steal half of MGI's sales ..... estimates for MGI in response to NeoPharm 's failed trial. However, any …
-
NeoPharm's Lead Drug Fails
We're putting NeoPharm NEOL under review while we digest the news that its lead drug has failed in a key clinical trial. The company announced on Monday that …
-
NeoPharm Cuts Costs in 3Q
NeoPharm 's NEOL third-quarter loss narrowed by 24 ..... pleased with these results, much of NeoPharm 's value continues to rest solidly on ..... We are a bit more cautious regarding NeoPharm 's liposomal portfolio; we should have …
-
Stock Star Rating Performance Update
… 06 No Change -41 Educate EEEE 10-11-05 -17 -41 NeoPharm NEOL 11-02-05 -28 -38 Journal Register JRC 01-19 ..... initial 5-star rating--are a study in contrasts. NeoPharm NEOL is a tiny, high-risk biotech with almost no current …
-
NeoPharm Awaits Final IL13 Results
NeoPharm 's NEOL management has been eagerly awaiting ..... efficacy analysis two weeks ago. Today, NeoPharm announced that the committee recommended ..... fair value estimate of $10 per share. NeoPharm 's stock continues to be volatile …